Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026)
Kyverna Therapeutics (KYTX) reported Debt Ratio of 0.1 for Q1 2026, up 14.64% quarter-over-quarter from 0.08 in Q4 2025.
Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026) Analysis & Trends
Kyverna Therapeutics has reported Debt Ratio for 2 years, with the latest figure at 0.1 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.1; the trailing twelve-month figure through Mar 2026 stood at 0.1 (changed N/A YoY), and the FY2025 full-year result was 0.08, changed N/A from the prior year.
- Debt Ratio for Q1 2026 stood at 0.1, up from 0.08 in the prior quarter.
- The five-year high for Debt Ratio was 0.1 in Q1 2026, with the low at 0.08 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.18 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Kyverna Therapeutics | 492.54 Mn | 259.59 Mn | - | 0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.10 |
| Dec 31, 2025 | 0.08 |